media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Medical equipment giant begins layoffs and factory closures

Cardinal Health, a global medical device giant, recently announced a major decision to close its factory in Tullamore, County O’Farley, Ireland in the spring of 2026 and cease production of a product. This decision will result in approximately 315 employees losing their jobs. It is reported that the manufacturing operations of the factory will be relocated to Mexico and Costa Rica to better meet the needs of the company’s global business, manufacturing, and supply chain operations. Jiadeno announced this plan in September 2024 and stated that the first batch of layoffs will begin in March and April 2025, while the second batch of layoffs will take place in April and May 2026. 01. The final shutdown date is May 2026 The history of Tullamore factory can be traced back to 1982, when it was established by Sherwood Medical. Over time, the factory has undergone multiple changes of ownership. In 1998, ...
- Source: drugdu
- 68
- April 3, 2025
Pharmtech Ingredients

Organiser: ITE Group Time: November 25-28, 2025 Address: 65-66 km Moscow Ring Road, Krasnogorsk, Russia Exhibition hall: Crocus-Expo IEC Product range: Pharmaceutical Machinery: Formulation production equipment, pharmaceutical water systems, traditional medicine processing equipment, refrigeration units, etc. Packaging Equipment & Materials: Aluminum-plastic packaging machines, filling machines, tablet presses, labeling machines, coding machines, anti-counterfeit printing and packaging, barcode composite technology equipment, adhesive label printing machines, plastic packaging products, container forming/filling/sealing machines, cartoning machines, bagging machines, multi-functional bottling lines, glass packaging, and pharmaceutical packaging material production equipment. Lab Equipment & Analysis: Laboratory instruments, consumables, chemical reagents, biochemical/analytical instruments, biotech testing equipment, pharmaceutical QA/QC devices, food analysis tools, medical industry analyzers. Fluid Handling Systems: Sanitary pumps, valves, fluid engineering, pipelines and fittings, microfiltration/ultrafiltration systems. Cleanroom Technology: Clean air-conditioning systems, clean workstations/tables, sterilization equipment, anti-static clothing. Pharmaceutical Excipients: Packaging materials, excipients, and related production equipment. Biotechnology: Biotech products and applications, fermenters, vaccines and enzymes, bio-facility infrastructure. About ...
- Source: drugdu
- 47
- April 3, 2025
Cultivate “Innovation Skills” and Cultivate “Conscience Seedlings”

After 14 years of deep cultivation in the vaccine track, Aim Vaccine’s innovative achievements have gradually blossomed, and it has embarked on a small, beautiful, refined and specialized road of special vaccine research and development in the global market. In March this year, the company’s mRNA herpes zoster vaccine obtained clinical trial approval from the U.S. Food and Drug Administration (FDA); mRNA RSV (respiratory syncytial virus) vaccine was approved for clinical trials in the United States in February; by the end of 2024, the company’s two blockbuster single-product vaccines will iterate serum-free rabies vaccine and 13-valent pneumococcal conjugate vaccine, obtain corresponding production licenses, and submit a listing registration application. “For traditional products, ‘the last one standing will win’, and for high-end single products, ‘all will prosper together’. We firmly believe that focusing on the research and development of iterative vaccine series is the real growth engine in the future, which ...
- Source: drugdu
- 63
- April 3, 2025
Zhifei Biotech’s adjuvanted trivalent influenza vaccine has obtained clinical trial approval, which is expected to further enrich the company’s virus vaccine varieties

Zhifei Biotech announced on the evening of April 1 that the trivalent influenza virus split vaccine (ZFA02 adjuvant) (referred to as “adjuvanted trivalent influenza vaccine”) developed by its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. has recently obtained the National Drug Administration’s drug clinical trial approval notice (notice number: 2025LP00953), agreeing to conduct clinical trials to prevent influenza caused by vaccine-related influenza viruses. The company stated that it will carry out relevant clinical trials as soon as possible according to the requirements of the clinical trial approval. It is understood that influenza is an acute respiratory infectious disease caused by influenza virus that can cause large-scale epidemics. It is highly contagious and can cause complications such as pneumonia, bronchitis, and myocarditis. It can also aggravate the basic diseases of high-risk groups such as the elderly and the weak. Vaccination against influenza is the most economical and effective measure to ...
- Source: drugdu
- 66
- April 3, 2025
Under the vaccine price war, the performance of the leading influenza vaccine company Hualan Vaccine in 2024 has stalled

Recently, Hualan Vaccine (301207.SZ), a domestic influenza vaccine manufacturer, released its 2024 annual report: the company achieved revenue of 1.128 billion yuan, a year-on-year decrease of 53.21%; net profit attributable to the parent company was 206 million yuan, a year-on-year decrease of 76.10%; net profit attributable to the parent company after deducting non-recurring items was 120 million yuan, a year-on-year decrease of 84.12%. Regarding the rapid decline in performance this time, Hualan Vaccine pointed out that due to multiple factors such as the reduction in influenza vaccine prices, fluctuations in vaccination rates among the public, changes in market demand and declining sales, the company’s business development and profitability were under great pressure, resulting in a significant decline in performance in 2024. Quadrivalent influenza vaccine is in full competition, and the price war has begun It is worth noting that Hualan Vaccine’s main sales product is influenza vaccine, and its product ...
- Source: drugdu
- 67
- April 3, 2025
Winning the first generic product! Huabang Pharmaceutical enters the market with strength

Recently, the topical drug calcipotriol-betamethasone ointment for the treatment of psoriasis developed by Chongqing Huabang Pharmaceutical was approved for marketing by the State Food and Drug Administration, becoming the first generic drug of calcipotriol-betamethasone ointment in China . Behind this is the story of how Huabang Pharmaceutical’s “China Solution” took ten years of research and development to finally break the 16-year market monopoly of original drugs in China. Ten Years of Breakthrough of the “China Solution” Calcipotriol-betamethasone ointment was originally developed by LEO Pharma and first launched in Denmark in March 2001. It was subsequently launched in many European countries and the United States (2006) and in China in September 2008 (trade name: Defubao). This product is a compound preparation of calcipotriol and betamethasone dipropionate. It inhibits the proliferation of keratinocytes through the vitamin D analog calcipotriol, combined with the anti-inflammatory, antipruritic, vasoconstrictive and immunosuppressive effects of betamethasone dipropionate, making ...
- Source: drugdu
- 67
- April 3, 2025
Entering a new era, medical device giants have reached a latest cooperation agreement

According to foreign media reports, medical device giant Solventum recently announced a strategic partnership with digital dental company SprintRay to jointly promote the application of disruptive 3D printing technology in the field of dental restoration. It is reported that this cooperation aims to meet the daily diagnosis and treatment needs of dentists for permanent restorations such as crown restorations, embedded restorations, and high embedded restorations through chair side 3D printing technology. The related research and commercialization process will focus on the full process solution for completing the restoration treatment on the same day. According to the announcement, the dental solutions division of Shuwannuo will integrate its cutting-edge materials science and big data analysis capabilities, integrating its subsidiary Filtek Easy Matching Universal Restoration Materials, Filtek Matrix Systems, Scotchbond Universal Adhesives, and RelyX ™ Core products such as self-adhesive resin cement. SprintRay will provide an end-to-end 3D printing ecosystem for chair side ...
- Source: drugdu
- 47
- April 2, 2025
Another ‘innovative medical device’ approved for market launch

Recently, the National Medical Products Administration approved the registration application for the innovative product “Disposable Pressure Monitoring Radiofrequency Ablation Catheter” of Hunan Aptech Medical Equipment Co., Ltd. (hereinafter referred to as Aptech Medical). Another flagship product has been approved Established in 2006, Aptech Medical is a wholly-owned subsidiary of Shenzhen Huitai Medical Equipment Co., Ltd. (hereinafter referred to as Huitai Medical). Epert Medical is a high-tech enterprise specializing in the research, development, production, and sales of cardiac electrophysiology and interventional medical devices. Currently, it has formed a business layout with complete coronary access and cardiac electrophysiology medical devices as the main focus, and peripheral vascular and neural interventional medical devices as the key development direction. It is understood that the disposable pressure monitoring radiofrequency ablation catheter from Epert Medical is composed of a head end, a tube body, a handle, a cable, a saline connector, and an optoelectronic hybrid plug. ...
- Source: drugdu
- 49
- April 2, 2025
Cultivate “Innovation Skills” and Cultivate “Conscience Seedlings”

After 14 years of deep cultivation in the vaccine track, AIM Vaccine’s innovative achievements have gradually blossomed, and it has embarked on a small, beautiful, refined and specialized road of special vaccine research and development in the global market. In March this year, the company’s mRNA herpes zoster vaccine obtained clinical trial approval from the U.S. Food and Drug Administration (FDA); mRNA RSV (respiratory syncytial virus) vaccine was approved for clinical trials in the United States in February; by the end of 2024, the company’s two blockbuster single-product vaccines will iterate serum-free rabies vaccine and 13-valent pneumococcal conjugate vaccine, obtain corresponding production licenses, and submit a listing registration application. “For traditional products, ‘the last one standing will win’, and for high-end single products, ‘all will prosper together’. We firmly believe that focusing on the research and development of iterative vaccine series is the real growth engine in the future, which ...
- Source: drugdu
- 51
- April 2, 2025
The “magnetic attraction” of the Chinese market is strong, and foreign companies are investing in China

AstraZeneca announced that it will establish its sixth global strategic R&D center in Beijing, BASF is building an integrated production base with a total investment of approximately 10 billion euros in Zhanjiang, Guangdong, and Shanghai Pudong has welcomed 13 regional headquarters of multinational companies and 4 foreign-funded R&D centers… Recently, foreign executives have visited China intensively, major projects have been frequently implemented, and policies to stabilize foreign investment have continued to increase. China’s “magnetic attraction” to attract foreign investment is strong. Many heads of foreign-funded enterprises said that China’s super-large market, complete production and supply chain system and scientific and technological innovation capabilities are huge opportunities. Investing in China is to go hand in hand with opportunities. They are willing to continue to expand investment in China and open up innovative cooperation space. Foreign-funded enterprises have cast their votes of confidence with “real money”, and cutting-edge innovation fields such as ...
- Source: drugdu
- 42
- April 2, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.